Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30924714 | 1.00 | PRCP (0.58) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL28409392 | 0.88 | PRCP (0.46) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL29568322 | 0.78 | CHRNB2 (0.44) | TSHRMAPTDRD1 | |
| SCHEMBL14395237 | 0.78 | CHRNB2 (0.44) | TSHRMAPTDRD1 | |
| SCHEMBL30368634 | 0.78 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL24017043 | 0.78 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL359803 | 0.78 | CHRNB2 (0.44) | TSHRMAPTDRD1 | |
| SCHEMBL16799768 | 0.78 | PRCP (0.70) | PRCPGAATSHRNPSR1SLC22A1 | |
| SCHEMBL1388248 | 0.77 | TSHR (0.73) | PRCPGAATSHRNPSR1SLC22A1 | |
| Bromide SCHEMBL3966126 | 0.77 | CHRNB2 (0.42) | TSHRMAPTDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | claimed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | claimed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | claimed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | claimed |
| WO-1997023484-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1997-07-03 | — | — | WO | claimed |
| EP-0135084-A2 | Tetrahydroisoquinolincarbamic-acid esters, process for their preparation and their use as pesticides | BAYER AG (DE) | 1985-03-27 | — | — | EP | claimed |
| CN-109890797-B | Substituted carbon nucleoside derivatives useful as anticancer agents | 辉瑞公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11566054-B2 | Peptides and compositions for prevention of cell adhesion and methods of using same | DISPERSEBIO LTD. (IL) | 2023-01-31 | — | — | US | disclosed |
| CN-115335369-A | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-114585614-A | Non-peptide somatostatin type 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114269922-A | Methods for modulating splicing | 斯基霍克疗法公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108884126-B | Compounds for treating eye disorders or diseases | 广州康睿生物医药科技股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
| WO-1997023484-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1997-07-03 | — | — | WO | disclosed |
| EP-0135084-A2 | Tetrahydroisoquinolincarbamic-acid esters, process for their preparation and their use as pesticides | BAYER AG (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0135084-A2 | Tetrahydroisoquinolincarbamic-acid esters, process for their preparation and their use as pesticides | BAYER AG (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0038177-B1 | ANTIALLERGIC IMIDODISULFAMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | disclosed |
| US-4315935-A | INHIBITING THE SYMPTOMS OF ASTHMA | SMITHKLINE CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0038177-A1 | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PRCP 4581/4885GAA 3982/4885TSHR 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.